Mutation of the NPM1 gene contributes to the development of donor cell–derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia

Donor‐derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response

“…While the results fail to discern a statistical difference in DD‐MDS/AL at 15 years after transplant between the various HSC sources, it could be argued that recipients of peripheral blood and UCB might have a higher earlier incidence and potentially a higher overall occurrence if longer length of follow up was similar for all groups. Still, the median follow up was >5 years in all groups, which is probably the highest risk period for the majority of patients based on this and other reports (Hertenstein et al , ; Ruiz‐Argüelles et al , ; Wang et al , ; Wiseman, ; Fraser et al , ; Matsunaga et al , ; Sevilla et al , ; Yamazaki et al , ; Gustafsson et al , ; Rodriquez‐Macias et al , ; Nakamizo et al , ). Even if the follow‐up period is restricted to an earlier time point, the incidence of DD‐MDS/AL after bone marrow transplant [0·10% (95%CI, 0–0·30%)] is not sufficiently different from that observed in recipients of peripheral blood or UCB transplant [0·56% (95%CI, 0–1·36%) and 0·56% (95%CI, 0–1·10%)] to reach statistical significance ( P = 0·16).…”

“…Donor‐derived myelodysplastic syndrome and acute leukaemia (DD‐MDS/AL) are rare adverse events after allogeneic haematopoietic stem cell (HSC) transplantation. Originally identified in 1971 (Fialkow et al , ), nearly 90 cases have now been reported in the literature (Hertenstein et al , ; Ruiz‐Argüelles et al , ; Wang et al , ; Wiseman, ; Fraser et al , ; Matsunaga et al , ; Sevilla et al , ; Yamazaki et al , ; Gustafsson et al , ; Rodriquez‐Macias et al , ; Nakamizo et al , ). Based on several reviews, the incidence of DD‐MDS/AL has been estimated to be between 0·12% and 5% (Hertenstein et al , ; Ruiz‐Argüelles et al , ; Wang et al , ; Wiseman, ).…”

“…Since the first documented cases in 2005, reports of DD‐MDS/DD‐AL after umbilical cord blood (UCB) transplantation have been more frequent than with other HSC sources (Fraser et al , ; Matsunaga et al , ; Sevilla et al , ; Yamazaki et al , ; Gustafsson et al , ; Rodriquez‐Macias et al , ; Nakamizo et al , ), causing some investigators to speculate that the incidence of DD‐MDS/AL may be higher after UCB relative to bone marrow or mobilized peripheral blood transplantation (Greaves, ; Greaves et al , ). Greaves et al () raised the important concern that UCB might carry an increased risk of DD‐MDS/AL due to the presence of these pre‐leukaemic clones previously shown to exist in a proportion of UCB samples (Greaves, ; Greaves et al , ).…”

iTRAQ‐Based Quantitative Proteomic Analysis of Nasopharyngeal Carcinoma

“…In addition, NPM1 is recognized as one of the most frequent targets of genetic alterations in hematopoietic cancers. In particular, NPM1 gene mutations have been implicated in the genesis, evolution [Dai and Ren, ; Noguera et al, ; Rodriguez‐Macias et al, ], relapse [Kronke et al, ], death evasion and drug sensitivity of acute myeloid leukemia (AML) [Lo et al, ]. On the other hand, NPM1 is ubiquitously overexpressed in solid tumors including gastric cancer [Tanaka et al, ; Yang et al, ], colon cancer [Liu et al, ; Wong et al, ], prostate cancer [Tsui et al, ], ovarian cancer [Shields et al, ], endometrial cancer [Chao et al, ], and breast cancer [Skaar et al, ].…”

Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients

“…The authors declare no conflict of interest. Wang et al 14 9 CML (3), ALL (2), AML (1) NHL (2) ALCL (1) MDS (7), AML (1), CLL (1) Xiao et al 15 1 AML AML Rodriguez-Macias et al 16 1 ALL AML Bobadilla-Morales et al 17 1 AML AML Ruiz-Delgado et al 18 7 ALL (6), PNH/AA (1) ALL (6), HCL (1) Hayes et al 19 1 ALL MS Kurosawa et al 20 1 CML ALL Hirsch et al 21 1 AML AML Gondek et al 7 2 AML (1), NHL (1) AML (1), MDS (1) Maestas et al 22 1 CML Myeloma Cutting et al 23 1 CML AML Total 108 ALL (32), CML (25), AML 23…”